p53 N-terminal binding and stabilisation by PIAS3 inhibits MDM2-induced p53 ubiquitination and regulates cell growth

Molecular Medicine Reports

Volumn 9, Issue 5, 2014, Pages 1903-1908

  Zhao, Ziyi ^a   Wu, Lan ^a   Shi, Huimin ^a   Wu, Chuanfang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cell cycle; Mouse double minute 2 homolog; p21; p53; Protein inhibitor of activated STAT3; Ubiquitination

Indexed keywords

AMINO ACID; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLOHEXIMIDE; MESSENGER RNA; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN INHIBITOR OF ACTIVATED STAT3; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CELL LINE; CELL LYSATE; COMPLEX FORMATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HALF LIFE TIME; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; STABLE EXPRESSION; TRANSACTIVATION; UBIQUITINATION;

CARRIER PROTEINS; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION; HUMANS; MOLECULAR CHAPERONES; PROTEIN BINDING; PROTEIN INHIBITORS OF ACTIVATED STAT; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 84899497886     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.1993     Document Type: Article

References (37)

1. Shaper NJ, Harrison M and Bates T: Impact of laparoscopic cholecystectomy on surgical training. Ann R Coll Surg Engl 78: 39-42, 1996.
2. Evans SC and Lozano G: The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 3: 390-395, 1997.
3. Attardi LD and Jacks T: The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci 55: 48-63, 1999.
4. Choi J and Donehower LA: p53 in embryonic development: maintaining a fine balance. Cell Mol Life Sci 55: 38-47, 1999.
5. Piette J, Neel H and Maréchal V: Mdm2: keeping p53 under control. Oncogene 15: 1001-1010, 1997.
6. Karanicolas J and Brooks CL III: The structural basis for biphasic kinetics in the folding of the WW domain from a forming-binding protein: Lessons for protein design? Proc Natl Acad Sci USA 100: 3954-3959, 2003.
7. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ and Pavletich NP: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953, 1996.
8. Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
9. Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997.
10. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF and Sherr CJ: Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95: 8292-8297, 1998.
11. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C and DePinho RA: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723, 1998.
12. Honda R and Yasuda H: Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18: 22-27, 1999.
13. Tao W and Levine AJ: P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 96: 6937-6941, 1999.
14. Weber JD, Taylor LJ, Roussel MF, Sherr CJ and Bar-Sagi D: Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1: 20-26, 1999.
15. Shadfan M, Lopez-Pajares V and Yuan ZM: MDM2 and MDMX: Alone and together in regulation of p53. Transl Cancer Res 1: 88-89, 2012.
16. Chen J, Marechal V and Levine AJ: Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13: 4107-4114, 1993.
17. Momand J, Zambetti GP, Olson DC, George D and Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
18. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J and el-Deiry WS: The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol Ther 1: 47-55, 2002.
19. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
20. Martin K, Trouche K, Hagemeier C, Sørensen TS, La Thangue NB and Kouzarides T: Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691-694, 1995.
21. Lughran O and La Thangue NB: Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol Cell Biol 20: 2186-2197, 2000.
22. Grossman SR, Perez M, Kung AL, et al: P300/MDM2 complexes participate in Mdm2-mediated p53 degradation. Mol Cell 2: 405-415, 1998.
23. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS and Kelly K: Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89: 1175-1184, 1997.
24. Kubbutat MH, Jones SN and Vousden KH: Regulation of p53 stability by Mdm2. Nature 387: 299-303, 1997.
25. Yu ZK, Geyer RK and Maki CG: MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogen 19: 5892-5897, 2000.
26. Fang S, Jensen JP, Ludwig RL, Vousden KH and Weissman AM: Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275: 8945-8951, 2000.
27. Geyer RK, Yu ZK and Maki CG: The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol 2: 569-573, 2000.
28. Xirodimas DP, Stephen CW and Lane DP: Compartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res 270: 66-77, 2001.
29. Barak Y, Juven T, Haffner R and Oren M: Mdm2 expression is induced by wild type p53 activity. EMBO J 12: 461-468, 1993.
30. Durocher D and Jackson SP: DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 13: 225-231, 2001.
31. Chehab NH, Malikzay A, Stavridi ES and Halazonetis TD: Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 96: 13777-13782, 1999.
32. Dumaz N, Milne DM, Jardine LJ and Meek DW: Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. Biochem J 359: 459-464, 2001.
33. Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M and Haupt Y: Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 18: 1805-1814, 1999.
34. Stindt MH, Carter S, Vigneron AM, Ryan KM, and Vousden KH: MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity. Cell Cycle 10: 3176-3188, 2001.
35. Lee SW, Lee MH, Park JH, Kang SH, Yoo HM, Ka SH, Oh YM, Jeon YJ and Chung CH: SUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damage. EMBO J 31: 4441-4452, 2012.
36. Lin J, Chen J, Elenbaas B and Levine AJ: Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 8: 1235-1246, 1994.
37. Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, Byeon IJ, Gabizon R, Mattia M, Zupnick A, Brown LM, Friedler A and Prives C: The C-terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol 17: 982-989, 2010.